We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Promising Therapy for Alzheimer's

By Biotechdaily staff writers
Posted on 26 Apr 2005
In what may prove to be a landmark development, a new clinical study has provided encouraging evidence that antibodies derived from human plasma can capture the beta-amyloid protein in blood and exert positive effects on the thinking abilities of patients with Alzheimer's disease (AD).

Intravenous immunoglobulin (IVIg) has been found to contain antibodies that latch onto beta-amyloid proteins in the blood. More...
Prior studies have shown that these antibodies can draw beta-amyloid out of the nervous system and reduce the burden of amyloid on the brain. However, AD patients were found to have lower levels of anti-amyloid antibodies in their blood than cognitively normal individuals their age. Later on, researchers discovered that IVIg contained antibodies to several forms of beta-amyloid, including those thought to play a central role in the development of AD.

In the phase I trial, eight AD patients were treated with IVIg and, to date, seven have undergone cognitive testing after six months of therapy. The testing showed that cognitive function not only stopped declining in all seven patients but also improved in six of the seven.

"If these results are confirmed in larger, controlled trials, we might have a safe Alzheimer's treatment capable of clearing the amyloid protein away,” observed senior researcher Dr. Marc E. Weksler, professor of geriatric medicine at Weill Cornell Medical College (New York, NY, USA).

The AD patients on the study had mild-to-moderate AD and averaged 74 years of age. They received one to four IVIg infusions per month at varying doses. Since the researchers wanted to track circulating levels of beta-amyloid and beta-amyloid antibodies, patients also underwent regular blood tests, as well as spinal taps to collect samples of spinal fluid. Patients were also given standard tests of memory and cognition to assess ongoing changes in their mental function. The study findings were presented at the annual meeting of the American Academy of Neurology in Miami (FL, USA) in April 2005.

In spite of the encouraging results, the scientists and doctors involved remained cautious. "Right now, we'd advise doctors against treating Alzheimer's patients with IVIg,” they stated. "There's still too much we don't know--especially the treatment's long-term effectiveness. We need to confirm these findings in larger, controlled trials before we can say anything definite.”





Related Links:
Weill Cornell Medical Center

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Silver Member
Connectivity Solution
EKF Link
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.